APAC Biopharmaceutical Third Party Logistics Market Report Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030

APAC biopharmaceutical third party logistics market, worth USD 13-14 Bn, is growing due to biologics demand, manufacturing expansion in China, India, Japan, and tech advancements like IoT.

Region:Asia

Author(s):Dev

Product Code:KRAB1943

Pages:92

Published On:January 2026

About the Report

Base Year 2024

APAC Biopharmaceutical Third Party Logistics Market Overview

  • The APAC Biopharmaceutical Third Party Logistics Market is valued at approximately USD 13–14 billion, based on a five-year historical analysis and its share within the global biopharmaceutical third party logistics space. This growth is primarily driven by the increasing demand for biopharmaceuticals, expanding biologics and biosimilars pipelines, advancements in healthcare infrastructure, and the rising need for efficient supply chain solutions to manage temperature-sensitive products. The market is also supported by the growing trend of outsourcing logistics services by pharmaceutical and biotechnology companies to specialized third party providers to enhance operational efficiency, reduce capital expenditure, and leverage advanced digital tools such as real?time tracking and data?driven route optimization.
  • Key players in this market include China, India, and Japan, which dominate due to their robust pharmaceutical and biopharmaceutical manufacturing capabilities, large patient populations, and significant investments in healthcare and logistics infrastructure. These countries have established themselves as major hubs for biopharmaceutical production and distribution, supported by export?oriented manufacturing in China and India and strong innovation and quality standards in Japan, attracting both domestic and international logistics providers to cater to the growing demand for temperature?controlled and compliant third?party logistics services.
  • In 2023, the Indian government implemented the National Logistics Policy, issued by the Ministry of Commerce and Industry, aimed at enhancing the efficiency of logistics services across the country. This policy focuses on improving multimodal infrastructure through initiatives such as the PM Gati Shakti National Master Plan, reducing logistics costs as a share of GDP, and promoting the use of digital platforms (such as Unified Logistics Interface Platform and Logistics Ease Across Different States index) in logistics operations, thereby facilitating better supply chain management for biopharmaceuticals and other sectors through improved coordination, faster transit times, and standardized service quality.

APAC Biopharmaceutical Third Party Logistics Market Segmentation

By Supply Chain Type:The supply chain type segmentation includes Cold Chain Logistics and Non-Cold Chain Logistics. Cold Chain Logistics is crucial for transporting temperature-sensitive biopharmaceuticals, including vaccines, biologics, and advanced therapies, ensuring product integrity and compliance with Good Distribution Practice and other regulatory standards. Non-Cold Chain Logistics, while also significant, primarily handles products that do not require temperature control and typically represents the larger share of overall pharmaceutical logistics volumes due to the high flow of conventional medicines. Globally, non-cold chain logistics has historically accounted for a higher share than cold chain in biopharmaceutical third party logistics, with cold chain expected to grow faster as demand for biologics and vaccines accelerates. Within APAC biopharmaceutical third party logistics, cold chain is expanding rapidly and its share is rising, though non-cold chain still holds a substantial proportion of the market.

APAC Biopharmaceutical Third Party Logistics Market segmentation by Supply Chain Type.

By Service Type:The service type segmentation encompasses Transportation, Warehousing & Storage, Value-Added Services (Packaging, Labelling, Kitting), and Others. Transportation is a critical service, as it directly impacts the timely and secure delivery of biopharmaceutical products to healthcare providers, distributors, and patients. Warehousing & Storage is also vital, providing GDP-compliant, temperature?controlled facilities for inventory management, consolidation, and quality assurance. Value-Added Services (such as secondary packaging, labelling, kitting, order fulfillment, and regulatory documentation support) are increasingly being adopted to enhance product handling, customization, and compliance and to enable integrated end?to?end solutions. At a global level, warehousing and storage has recently contributed the largest share of biopharmaceutical third party logistics revenue, while transportation remains the largest service category in the broader Asia Pacific pharmaceutical logistics market, indicating strong demand for both storage and transport services in APAC biopharma logistics.

APAC Biopharmaceutical Third Party Logistics Market segmentation by Service Type.

APAC Biopharmaceutical Third Party Logistics Market Competitive Landscape

The APAC Biopharmaceutical Third Party Logistics Market is characterized by a dynamic mix of regional and international players. Leading participants such as DHL Supply Chain, Kuehne + Nagel, DB Schenker, UPS Healthcare, FedEx, CEVA Logistics, GEODIS, Nippon Express, Kintetsu World Express, Yamato Transport, SF Express, Sinotrans, Kerry Logistics Network, CJ Logistics, Yusen Logistics contribute to innovation, geographic expansion, and service delivery in this space.

DHL Supply Chain

1969

Germany

Kuehne + Nagel

1890

Switzerland

DB Schenker

1872

Germany

UPS Healthcare

1907

USA

FedEx

1971

USA

Company

Establishment Year

Headquarters

APAC Biopharma 3PL Revenue (USD Million)

Revenue CAGR in APAC Biopharma 3PL (%)

APAC Market Share (%)

Share of Cold Chain Revenue (%)

EBITDA Margin from Biopharma 3PL (%)

Return on Invested Capital (ROIC) (%)

APAC Biopharmaceutical Third Party Logistics Market Industry Analysis

Growth Drivers

  • Increasing Demand for Temperature-Sensitive Biopharmaceuticals:The global market for temperature-sensitive biopharmaceuticals is projected to reach $300 billion in future, driven by the rising need for biologics and biosimilars. In the APAC region, the demand for cold chain logistics is expected to grow significantly, with an estimated 15% increase in temperature-controlled shipments. This surge is primarily due to the growing prevalence of chronic diseases, necessitating effective distribution of sensitive products.
  • Expansion of Biopharmaceutical Manufacturing Facilities in APAC:The APAC region has seen a substantial increase in biopharmaceutical manufacturing facilities, with over 200 new plants established in the last three years. This expansion is fueled by investments exceeding $10 billion from major pharmaceutical companies, aiming to enhance local production capabilities. As a result, the demand for third-party logistics services is expected to rise, necessitating efficient supply chain solutions to support these facilities.
  • Growth in E-commerce for Biopharmaceutical Products:The e-commerce sector for biopharmaceuticals in APAC is projected to grow to $50 billion in future, reflecting a 20% annual growth rate. This trend is driven by increased online sales channels and consumer preference for home delivery of medications. Consequently, logistics providers are adapting their services to meet the unique requirements of e-commerce, including real-time tracking and temperature control, enhancing overall service efficiency.

Market Challenges

  • Stringent Regulatory Requirements:The biopharmaceutical logistics sector faces rigorous regulatory frameworks, with compliance costs averaging $1 million per facility annually. Regulations such as Good Distribution Practice (GDP) and temperature control mandates require logistics providers to invest heavily in infrastructure and training. These stringent requirements can hinder operational flexibility and increase the time to market for biopharmaceutical products, posing a significant challenge for logistics companies.
  • High Operational Costs:Operational costs in the biopharmaceutical logistics sector are rising, with average expenses reaching $2.5 million per year for maintaining cold chain facilities. Factors contributing to these costs include energy consumption, specialized equipment, and workforce training. As logistics providers strive to maintain compliance and service quality, these high operational costs can limit profitability and deter new entrants into the market.

APAC Biopharmaceutical Third Party Logistics Market Future Outlook

The APAC biopharmaceutical third-party logistics market is poised for significant transformation, driven by technological advancements and evolving consumer expectations. The integration of IoT and AI technologies is expected to enhance operational efficiency, enabling real-time monitoring and predictive analytics. Additionally, as sustainability becomes a priority, logistics providers are likely to adopt greener practices, reducing their carbon footprint. These trends will shape the future landscape, fostering innovation and improving service delivery in the biopharmaceutical logistics sector.

Market Opportunities

  • Adoption of Advanced Technologies:The implementation of IoT and AI in logistics operations presents a significant opportunity, with potential cost savings of up to 30%. These technologies can streamline processes, enhance tracking capabilities, and improve inventory management, ultimately leading to better service delivery and customer satisfaction in the biopharmaceutical sector.
  • Strategic Partnerships with Local Players:Forming alliances with local logistics providers can enhance market penetration and operational efficiency. By leveraging local expertise and established networks, companies can reduce costs and improve service quality, positioning themselves favorably in the competitive APAC biopharmaceutical logistics landscape.

Scope of the Report

SegmentSub-Segments
By Supply Chain Type

Cold Chain Logistics

Non-Cold Chain Logistics

By Service Type

Transportation

Warehousing & Storage

Value-Added Services (Packaging, Labelling, Kitting)

Others

By End-User

Pharmaceutical Companies

Biotechnology Firms

Contract Research Organizations (CROs)

Contract Development and Manufacturing Organizations (CDMOs)

Hospitals, Clinics, and Specialty Pharmacies

Others

By Temperature Range

Ambient

Refrigerated (2°C–8°C)

Frozen (-20°C and below)

Deep-Frozen / Ultra-Low (-80°C and below)

By Mode of Transport

Road

Air

Sea

Rail

By Logistics Model

Third-Party Logistics (3PL)

Fourth-Party Logistics (4PL)

Integrated Logistics

Others

By Country

China

India

Japan

South Korea

Australia & New Zealand

Southeast Asia

Rest of APAC

Key Target Audience

Investors and Venture Capitalist Firms

Government and Regulatory Bodies (e.g., National Medical Products Administration, Therapeutic Goods Administration)

Biopharmaceutical Manufacturers

Third Party Logistics Providers

Pharmaceutical Distributors

Healthcare Providers and Institutions

Industry Associations (e.g., Asia Pacific Pharmaceutical Logistics Association)

Financial Institutions and Investment Banks

Players Mentioned in the Report:

DHL Supply Chain

Kuehne + Nagel

DB Schenker

UPS Healthcare

FedEx

CEVA Logistics

GEODIS

Nippon Express

Kintetsu World Express

Yamato Transport

SF Express

Sinotrans

Kerry Logistics Network

CJ Logistics

Yusen Logistics

Table of Contents

Market Assessment Phase

1. Executive Summary and Approach


2. APAC Biopharmaceutical Third Party Logistics Market Overview

2.1 Key Insights and Strategic Recommendations

2.2 APAC Biopharmaceutical Third Party Logistics Market Overview

2.3 Definition and Scope

2.4 Evolution of Market Ecosystem

2.5 Timeline of Key Regulatory Milestones

2.6 Value Chain & Stakeholder Mapping

2.7 Business Cycle Analysis

2.8 Policy & Incentive Landscape


3. APAC Biopharmaceutical Third Party Logistics Market Analysis

3.1 Growth Drivers

3.1.1 Increasing demand for temperature-sensitive biopharmaceuticals
3.1.2 Expansion of biopharmaceutical manufacturing facilities in APAC
3.1.3 Rising prevalence of chronic diseases
3.1.4 Growth in e-commerce for biopharmaceutical products

3.2 Market Challenges

3.2.1 Stringent regulatory requirements
3.2.2 High operational costs
3.2.3 Limited infrastructure in certain regions
3.2.4 Competition from local logistics providers

3.3 Market Opportunities

3.3.1 Adoption of advanced technologies (IoT, AI) in logistics
3.3.2 Strategic partnerships with local players
3.3.3 Expansion into emerging markets within APAC
3.3.4 Increasing investment in cold chain logistics

3.4 Market Trends

3.4.1 Growing focus on sustainability in logistics
3.4.2 Rise of digital platforms for logistics management
3.4.3 Increased demand for real-time tracking solutions
3.4.4 Shift towards integrated supply chain solutions

3.5 Government Regulation

3.5.1 Compliance with Good Distribution Practice (GDP)
3.5.2 Regulations on temperature control for biopharmaceuticals
3.5.3 Import/export regulations for biopharmaceutical products
3.5.4 Licensing requirements for logistics providers

4. SWOT Analysis


5. Stakeholder Analysis


6. Porter's Five Forces Analysis


7. APAC Biopharmaceutical Third Party Logistics Market Market Size, 2019-2024

7.1 By Value

7.2 By Volume

7.3 By Average Selling Price


8. APAC Biopharmaceutical Third Party Logistics Market Segmentation

8.1 By Supply Chain Type

8.1.1 Cold Chain Logistics
8.1.2 Non-Cold Chain Logistics

8.2 By Service Type

8.2.1 Transportation
8.2.2 Warehousing & Storage
8.2.3 Value-Added Services (Packaging, Labelling, Kitting)
8.2.4 Others

8.3 By End-User

8.3.1 Pharmaceutical Companies
8.3.2 Biotechnology Firms
8.3.3 Contract Research Organizations (CROs)
8.3.4 Contract Development and Manufacturing Organizations (CDMOs)
8.3.5 Hospitals, Clinics, and Specialty Pharmacies
8.3.6 Others

8.4 By Temperature Range

8.4.1 Ambient
8.4.2 Refrigerated (2°C–8°C)
8.4.3 Frozen (-20°C and below)
8.4.4 Deep-Frozen / Ultra-Low (-80°C and below)

8.5 By Mode of Transport

8.5.1 Road
8.5.2 Air
8.5.3 Sea
8.5.4 Rail

8.6 By Logistics Model

8.6.1 Third-Party Logistics (3PL)
8.6.2 Fourth-Party Logistics (4PL)
8.6.3 Integrated Logistics
8.6.4 Others

8.7 By Country

8.7.1 China
8.7.2 India
8.7.3 Japan
8.7.4 South Korea
8.7.5 Australia & New Zealand
8.7.6 Southeast Asia
8.7.7 Rest of APAC

9. APAC Biopharmaceutical Third Party Logistics Market Competitive Analysis

9.1 Market Share of Key Players

9.2 Cross Comparison of Key Players

9.2.1 Company Name
9.2.2 APAC Biopharma 3PL Revenue (USD Million)
9.2.3 Revenue CAGR in APAC Biopharma 3PL (%)
9.2.4 APAC Market Share (%)
9.2.5 Share of Cold Chain Revenue (%)
9.2.6 EBITDA Margin from Biopharma 3PL (%)
9.2.7 Return on Invested Capital (ROIC) (%)
9.2.8 On-Time, In-Full (OTIF) Delivery Rate (%)
9.2.9 GDP / GxP Compliance Score
9.2.10 Network Coverage (Number of APAC Sites / Countries Served)
9.2.11 Technology Enablement Index (Real-Time Tracking, IoT, Control Towers)
9.2.12 Customer Retention Rate (%)

9.3 SWOT Analysis of Top Players

9.4 Pricing Analysis

9.5 Detailed Profile of Major Companies

9.5.1 DHL Supply Chain
9.5.2 Kuehne + Nagel
9.5.3 DB Schenker
9.5.4 UPS Healthcare
9.5.5 FedEx
9.5.6 CEVA Logistics
9.5.7 GEODIS
9.5.8 Nippon Express
9.5.9 Kintetsu World Express
9.5.10 Yamato Transport
9.5.11 SF Express
9.5.12 Sinotrans
9.5.13 Kerry Logistics Network
9.5.14 CJ Logistics
9.5.15 Yusen Logistics

10. APAC Biopharmaceutical Third Party Logistics Market End-User Analysis

10.1 Procurement Behavior of Key Ministries

10.1.1 Budget Allocation Trends
10.1.2 Decision-Making Processes
10.1.3 Supplier Selection Criteria
10.1.4 Contract Management Practices

10.2 Corporate Spend on Infrastructure & Energy

10.2.1 Investment Trends in Logistics Infrastructure
10.2.2 Energy Efficiency Initiatives
10.2.3 Budgeting for Technology Upgrades
10.2.4 Others

10.3 Pain Point Analysis by End-User Category

10.3.1 Supply Chain Disruptions
10.3.2 Compliance Challenges
10.3.3 Cost Management Issues
10.3.4 Others

10.4 User Readiness for Adoption

10.4.1 Awareness of Logistics Solutions
10.4.2 Training and Support Needs
10.4.3 Technology Adoption Barriers
10.4.4 Others

10.5 Post-Deployment ROI and Use Case Expansion

10.5.1 Measurement of ROI
10.5.2 Case Studies of Successful Implementations
10.5.3 Future Use Case Opportunities
10.5.4 Others

11. APAC Biopharmaceutical Third Party Logistics Market Future Size, 2025-2030

11.1 By Value

11.2 By Volume

11.3 By Average Selling Price


Go-To-Market Strategy Phase

1. Whitespace Analysis + Business Model Canvas

1.1 Market Gaps Identification

1.2 Business Model Development


2. Marketing and Positioning Recommendations

2.1 Branding Strategies

2.2 Product USPs


3. Distribution Plan

3.1 Urban Retail vs Rural NGO Tie-Ups


4. Channel & Pricing Gaps

4.1 Underserved Routes

4.2 Pricing Bands


5. Unmet Demand & Latent Needs

5.1 Category Gaps

5.2 Consumer Segments


6. Customer Relationship

6.1 Loyalty Programs

6.2 After-Sales Service


7. Value Proposition

7.1 Sustainability

7.2 Integrated Supply Chains


8. Key Activities

8.1 Regulatory Compliance

8.2 Branding

8.3 Distribution Setup


9. Entry Strategy Evaluation

9.1 Domestic Market Entry Strategy

9.1.1 Product Mix
9.1.2 Pricing Band
9.1.3 Packaging

9.2 Export Entry Strategy

9.2.1 Target Countries
9.2.2 Compliance Roadmap

10. Entry Mode Assessment

10.1 JV

10.2 Greenfield

10.3 M&A

10.4 Distributor Model


11. Capital and Timeline Estimation

11.1 Capital Requirements

11.2 Timelines


12. Control vs Risk Trade-Off

12.1 Ownership vs Partnerships


13. Profitability Outlook

13.1 Breakeven Analysis

13.2 Long-Term Sustainability


14. Potential Partner List

14.1 Distributors

14.2 JVs

14.3 Acquisition Targets


15. Execution Roadmap

15.1 Phased Plan for Market Entry

15.1.1 Market Setup
15.1.2 Market Entry
15.1.3 Growth Acceleration
15.1.4 Scale & Stabilize

15.2 Key Activities and Milestones

15.2.1 Milestone Planning
15.2.2 Activity Tracking

Research Methodology

ApproachModellingSample

Phase 1: Approach1

Desk Research

  • Analysis of industry reports from biopharmaceutical associations and logistics organizations
  • Review of government publications and regulatory frameworks affecting biopharmaceutical logistics in APAC
  • Examination of market trends and forecasts from reputable market research databases

Primary Research

  • In-depth interviews with logistics managers at biopharmaceutical companies
  • Surveys targeting supply chain experts and consultants specializing in biopharmaceuticals
  • Field interviews with warehouse and distribution center supervisors in the biopharmaceutical sector

Validation & Triangulation

  • Cross-validation of findings through multiple data sources, including trade publications and expert opinions
  • Triangulation of quantitative data with qualitative insights from industry experts
  • Sanity checks conducted through peer reviews and expert panel discussions

Phase 2: Market Size Estimation1

Top-down Assessment

  • Estimation of total logistics spending in the biopharmaceutical sector across APAC countries
  • Segmentation of the market by service type (e.g., cold chain logistics, warehousing, transportation)
  • Incorporation of growth rates from emerging markets and established biopharmaceutical hubs

Bottom-up Modeling

  • Collection of operational data from leading third-party logistics providers in the biopharmaceutical space
  • Cost analysis based on service pricing models and operational efficiencies
  • Volume estimates derived from historical data and projected growth in biopharmaceutical production

Forecasting & Scenario Analysis

  • Utilization of econometric models to project future market growth based on current trends
  • Scenario planning based on potential regulatory changes and technological advancements
  • Development of baseline, optimistic, and pessimistic forecasts through 2030

Phase 3: CATI Sample Composition1

Scope Item/SegmentSample SizeTarget Respondent Profiles
Cold Chain Logistics Providers100Logistics Managers, Cold Chain Specialists
Biopharmaceutical Manufacturing Facilities80Operations Managers, Quality Assurance Leads
Regulatory Compliance Experts60Regulatory Affairs Managers, Compliance Officers
Distribution Network Analysts70Supply Chain Analysts, Distribution Managers
Technology Providers for Logistics50Product Managers, Technology Solutions Architects

Frequently Asked Questions

What is the current value of the APAC Biopharmaceutical Third Party Logistics Market?

The APAC Biopharmaceutical Third Party Logistics Market is valued at approximately USD 1314 billion, reflecting its significant share within the global biopharmaceutical logistics sector, driven by increasing demand for biopharmaceuticals and advancements in healthcare infrastructure.

What factors are driving the growth of the APAC Biopharmaceutical Third Party Logistics Market?

Which countries dominate the APAC Biopharmaceutical Third Party Logistics Market?

What is the significance of cold chain logistics in the biopharmaceutical sector?

Other Regional/Country Reports

Indonesia Biopharmaceutical Third Party Logistics Market

Malaysia Biopharmaceutical Third Party Logistics Market

KSA Biopharmaceutical Third Party Logistics Market

SEA Biopharmaceutical Third Party Logistics Market

Vietnam Biopharmaceutical Third Party Logistics Market

Thailand Biopharmaceutical Third Party Logistics Market

Why Buy From Us?

Refine Robust Result (RRR) Framework
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follow Robust, Refine and Result (RRR) methodology. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents' facts and opinions, and Result for presenting data with story.

Our Reach Is Unmatched
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Shifting the Research Paradigm
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

More Insights-Better Decisions
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Transparency and Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

Round the Clock Support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Clients Choose Us?

400000+
Reports in repository
150+
Consulting projects a year
100+
Analysts
8000+
Client Queries in 2022